{
    "Patient": {
        "Name": "Alison Jones",
        "DOB": "1941-07-04",
        "Sex": "Male",
        "Caseno": "4751",
        "Diagnosis": "Lobular carcinoma in situ (LCIS)",
        "Physician": "Dr. Wanda Nguyen"
    },
    "specimen information": {
        "primary_tumor_site": "Breast",
        "specimen_site": "Lymph nodes (axillary",
        "specimen_ID": "3372",
        "CollectedDate": "2024-03-30",
        "ReceivedDate": "2024-03-31",
        "Pathological Diagnosis": "Left breast, central, 12:00, suspicious mass, 12-gauge core needle biopsy: Infiltrating moderately-differentiated mammary carcinoma, grade 2, Nottingham score 6 (architectural grade 3, nuclear grade 2, mitotic figures 1).",
        "Dissection Information": "Molecular testing of this specimen was performed after harvesting of targeted tissues with an approved manual microdissection technique. Candidate slides were examined under a microscope and areas containing tumor cells (and separately normal cells, when necessary for testing) were circled. A laboratory technician harvested targeted tissues for extraction from the marked areas using a dissection microscope."
    },
    "Results with Therapy association": [
        {
            "Biomarker": "ER",
            "Method": "IHC",
            "Analyte": "protein",
            "Result": "Positive | 3+, 100%",
            "Therapy association": [
                "BENEFIT",
                "abemaciclib",
                "palbociclib",
                "ribociclib",
                "endocrine",
                "therapy",
                "everolimus"
            ],
            "Biomarker_level": "level 2"
        },
        {
            "Biomarker": "PR",
            "Method": "IHC",
            "Analyte": "protein",
            "Result": "Positive | 2+, 95%",
            "Therapy association": [
                "BENEFIT",
                "abemaciclib",
                "palbociclib",
                "ribociclib",
                "endocrine therapy"
            ],
            "Biomarker_level": "level 2"
        },
        {
            "Biomarker": "TMB",
            "Method": "Seq",
            "Analyte": "DNA tumor",
            "Result": "11 m/Mb Low",
            "Therapy association": [
                "BENEFIT",
                "pembrolizumab"
            ],
            "Biomarker_level": "level 2"
        },
        {
            "Biomarker": "ERBB2",
            "Method": "IHC",
            "Analyte": "Protien",
            "Result": "Negative | 0",
            "Therapy association": [
                "LACK OF BENEFT",
                "trastuzumab",
                "ado-trastuzumab emtansine",
                "pertuzumab",
                "fam-trastuzumab deruxtecan-nxki",
                "lapatinib",
                "neratinib",
                "tucatinib"
            ],
            "Biomarker_level": "level 1"
        }
    ],
    "Relevant Biomarkers": [
        {
            "BioMarker": "CHD6",
            "Method": "Seq",
            "Analyte": "RNA-Tumor",
            "Result": "Stable"
        },
        {
            "BioMarker": "PD-L1(SP142)",
            "Method": "IHC",
            "Analyte": "Protien",
            "Result": "Positive| 1+, 29%"
        },
        {
            "BioMarker": "CSF3R",
            "Method": "Seq",
            "Analyte": "RNA-Tumor",
            "Result": "Stable"
        },
        {
            "BioMarker": "PD-L1(SP142)",
            "Method": "IHC",
            "Analyte": "Protien",
            "Result": "Positive| 3+, 6%"
        },
        {
            "BioMarker": "PR",
            "Method": "IHC",
            "Analyte": "Protien",
            "Result": "Positive| 1+, 7%"
        },
        {
            "BioMarker": "Mismatch repair status",
            "Method": "IHC",
            "Analyte": "Protien",
            "Result": "Negative| 3+, 49%"
        },
        {
            "BioMarker": "PR",
            "Method": "IHC",
            "Analyte": "Protien",
            "Result": "Negative| 2+, 21%"
        },
        {
            "BioMarker": "PIK3CA",
            "Method": "Seq",
            "Analyte": "DNA-Tumor",
            "Result": "Stable"
        },
        {
            "BioMarker": "ER",
            "Method": "IHC",
            "Analyte": "Protien",
            "Result": "Negative| 3+, 62%"
        },
        {
            "BioMarker": "Mismatch repair status",
            "Method": "IHC",
            "Analyte": "Protien",
            "Result": "Positive| 2+, 89%"
        }
    ],
    "Genomic Signatures": [
        {
            "BioMarker": "Microsatellite instability",
            "Method": "Seq",
            "Analyte": "DNA tumor",
            "Result": "High"
        },
        {
            "BioMarker": "Tumor mutational burden",
            "Method": "Seq",
            "Analyte": "DNA tumor",
            "Result": "11 mutations/Mb Low"
        },
        {
            "BioMarker": "Genomic loss of heterozygosity (LOH)",
            "Method": "Seq",
            "Analyte": "DNA tumor",
            "Result": "High - 34% of tested genomic segments exhibit LOH"
        }
    ],
    "Genes Tested with Pathogenic Alterations": [
        {
            "Gene": "DPYD",
            "Method": "Seq",
            "Analyte": "DNA tumor",
            "Variant Interpretation": "Pathogenic",
            "Protien Alteration": "p.A374E",
            "Exon": 7,
            "DNA Alteration": ">",
            "Allele Frequency %": "27.28"
        },
        {
            "Gene": "PIK3CA",
            "Method": "Seq",
            "Analyte": "DNA tumor",
            "Variant Interpretation": "Pathogenic",
            "Protien Alteration": "p.N159Y",
            "Exon": 14,
            "DNA Alteration": "3",
            "Allele Frequency %": "11.28"
        },
        {
            "Gene": "CD74",
            "Method": "Seq",
            "Analyte": "DNA tumor",
            "Variant Interpretation": "Pathogenic",
            "Protien Alteration": "p.C481X",
            "Exon": 11,
            "DNA Alteration": "1",
            "Allele Frequency %": "21.45"
        },
        {
            "Gene": "PDGFRB",
            "Method": "Seq",
            "Analyte": "DNA tumor",
            "Variant Interpretation": "Pathogenic",
            "Protien Alteration": "p.G12D",
            "Exon": 14,
            "DNA Alteration": "c.35_36inv",
            "Allele Frequency %": "1.29"
        }
    ],
    "Gene variants of unknown significance": [
        {
            "Gene": "CALR",
            "Method": "Seq",
            "Analyte": "DNA tumor",
            "Variant Interpretation": "Variant of uncertain significance",
            "Protien Alteration": "p.N515H",
            "Exon": 14,
            "DNA Alteration": "A",
            "Allele Frequency %": "8.82"
        },
        {
            "Gene": "SDHB",
            "Method": "Seq",
            "Analyte": "DNA tumor",
            "Variant Interpretation": "Variant of uncertain significance",
            "Protien Alteration": "p.L122R",
            "Exon": 5,
            "DNA Alteration": "c.365T>G",
            "Allele Frequency %": "24.79"
        },
        {
            "Gene": "JAK3",
            "Method": "Seq",
            "Analyte": "DNA tumor",
            "Variant Interpretation": "Variant of uncertain significance",
            "Protien Alteration": "p.P904L",
            "Exon": 16,
            "DNA Alteration": "c.2711C>T",
            "Allele Frequency %": "1.11"
        },
        {
            "Gene": "ZEB2",
            "Method": "Seq",
            "Analyte": "DNA tumor",
            "Variant Interpretation": "Variant of uncertain significance",
            "Protien Alteration": "p.K860I",
            "Exon": 19,
            "DNA Alteration": "c.2238_2252del15",
            "Allele Frequency %": "2.88"
        },
        {
            "Gene": "CDC73",
            "Method": "Seq",
            "Analyte": "DNA tumor",
            "Variant Interpretation": "Variant of uncertain significance",
            "Protien Alteration": " p.W266*",
            "Exon": 3,
            "DNA Alteration": " c.798G>A",
            "Allele Frequency %": "2.08"
        }
    ],
    "Immunohistochemistry results": [
        {
            "Biomarker": "AR",
            "Result": "Negative| 2+, 4%"
        },
        {
            "Biomarker": "PTEN",
            "Result": "Negative| 1+, 74%"
        },
        {
            "Biomarker": "PR",
            "Result": "Positive| 3+, 85%"
        },
        {
            "Biomarker": "MSH2",
            "Result": "Positive| 3+, 69%"
        },
        {
            "Biomarker": "MLH1",
            "Result": "Negative| 1+, 7%"
        },
        {
            "Biomarker": "ERBB2",
            "Result": "Negative| 2+, 12%"
        },
        {
            "Biomarker": "PMS2",
            "Result": "Positive| 1+, 40%"
        }
    ],
    "Genes Tested with indeterminate results": [
        "JAK2",
        "DICER1",
        "PIK3CA",
        "SDHD"
    ],
    "Chemotherapy clinical trials": [
        {
            "Drug class": "Anti hormonal therapy",
            "Biomarker": "ER",
            "Method": "IHC",
            "Analyte": "protein",
            "Investigational agents": [
                "anastrazole",
                "letrozole",
                "exemestane",
                "fulvestrant",
                "tamoxifen",
                "goserelin",
                "leuprolide"
            ]
        },
        {
            "Drug class": "Anti hormonal therapy",
            "Biomarker": "PR",
            "Method": "IHC",
            "Analyte": "protein",
            "Investigational agents": [
                "anastrazole",
                "letrozole",
                "exemestane",
                "fulvestrant",
                "tamoxifen",
                "goserelin",
                "leuprolide"
            ]
        },
        {
            "Drug class": "Anti inflammatory agents",
            "Biomarker": "PIK3CA",
            "Method": "NGS",
            "Analyte": "DNA tumor",
            "Investigational agents": [
                "aspirin"
            ]
        }
    ],
    "Targeted therapy clinical trials": [
        {
            "Drug class": "Akt inhibitors",
            "Biomarker": "ARID1A",
            "Method": "NGS",
            "Analyte": "DNA tumor",
            "Investigational agents": [
                "AZD5363",
                "MK-2206",
                "ipataserib"
            ]
        },
        {
            "Drug class": "immunomodulatory agents",
            "Biomarker": "TMB",
            "Method": "NGS",
            "Analyte": "DNA tumor",
            "Investigational agents": [
                "avelumab",
                "atezolizumab",
                "durvalumab",
                "ipilimumab",
                "nivolumab",
                "pembrolizumab"
            ]
        },
        {
            "Drug class": "PARP inhibitors",
            "Biomarker": "NBN",
            "Method": "NGS",
            "Analyte": "DNA tumor",
            "Investigational agents": [
                "BGB-290",
                "BMN-673",
                "olaparib",
                "rucaparib",
                "talazoparib"
            ]
        },
        {
            "Drug class": "Akt/mTor inhibitors",
            "Biomarker": "PIK3CA",
            "Method": "NGS",
            "Analyte": "DNA tumor",
            "Investigational agents": [
                "AZD5363",
                "BYL719",
                "MK-2206",
                "ipataserib",
                "everolimus",
                "temsirolimus"
            ]
        }
    ]
}